更新于：2024-11-18
Fluvoxamine Maleate
马来酸氟伏沙明
更新于：2024-11-18
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C19H25F3N2O6 |
InChIKeyLFMYNZPAVPMEGP-PIDGMYBPSA-N |
CAS号61718-82-9 |
关联
105
项与 马来酸氟伏沙明 相关的临床试验马来酸氟伏沙明片在健康成年受试者中空腹和餐后状态下生物等效性试验
- ASN51-104
Phase 1, Open-Label, Parallel Group Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP2C19 Inhibitor), Itraconazole (CYP3A4 Inhibitor) and Paroxetine (CYP2D6 Inhibitor) on the Pharmacokinetics of ASN51 in Healthy Subjects
100 项与 马来酸氟伏沙明 相关的临床结果
登录后查看更多信息
100 项与 马来酸氟伏沙明 相关的转化医学
登录后查看更多信息
100 项与 马来酸氟伏沙明 相关的专利（医药）
登录后查看更多信息
2,887
项与 马来酸氟伏沙明 相关的文献（医药）2025-01-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
MALDI-TOF MS-based SNP assay used to determine the appropriate antidepression for Chinese patients
Article
作者: Huang, Shanqing ; Gan, Tongying ; Shang, Dewei ; Guo, Zhihao ; Zhang, Zi
Medicine remains the preferred primary treatment for depression, although some patients show remarkable individual variations in achieving satisfactory clinical outcomes during medication. Genetic polymorphisms cause approximately 40 % of individual differences in treatment response. Therefore, this study aimed to develop a technique to identify single nucleotide polymorphisms (SNPs) associated with the metabolism, effectiveness, and side effects of antidepressant medications in Chinese patients. Bibliometrics was used to search literature related to "depression" and "SNP" in Web of Science. The obtained SNP information was screened using the PharmGKB database. By designing and optimizing primers and conducting a compound amplification system, a method was established based on MALDI-TOF MS to detect polymorphisms associated with the antidepressant drugs, including sertraline, fluoxetine, citalopram, escitalopram, venlafaxine, fluvoxamine, paroxetine, and mirtazapine. The accuracy and sensitivity of the established method were verified by Sanger sequencing. A total of 10,043 articles were screened from the database, and 46 SNPs with a mutation frequency of >1 % in Asian populations and annotated with relevant clinical drugs were extracted from the PharmGKB database. This method was compared with the results of Sanger sequencing, and the accuracy of the detection results was 100 %. The MALDI-TOF MS-based SNP assay developed in this study can be a fast, convenient and effective way for patients to find the right medication for themselves. Moreover, we found that this SNP assay holds the promise of being a potential reference tool for assessing individualised differences in drug efficacy, not only for screening the causes of poor antidepressant efficacy in patients after taking medication, but also for advising physicians to understand individualised differences in drug efficacy.
2024-12-01PHYTOMEDICINE
Prebiotic inulin alleviates anxiety and depression-like behavior in alcohol withdrawal mice by modulating the gut microbiota and 5-HT metabolism
Article
作者: Wei, Wei ; Zheng, Xinjian ; Xu, Chongchong ; Yang, Shuo ; Wang, Yue ; Li, Kuan ; Bao, Jianjun ; Wang, Shixu ; Zhong, Shurong ; Zhang, Xulan ; Lian, Xinqing
BACKGROUND:
Alcohol dependence (AD) is a common psychiatric disorder, often accompanied by anxiety and depression. These comorbidities are linked to disturbances in serotonin (5-HT) metabolism and gut microbiota dysbiosis. Clinical studies suggest that inulin, a prebiotic, can alleviate anxiety and depression in AD patients by affecting the gut microbiota, although the mechanisms remain unclear.
PURPOSE:
The purpose of this study is to investigate the potential mechanisms by which inulin, a prebiotic, improves anxiety and depression-like behaviors in AD withdrawal mice. This research is based on the drug and food homology and intestinal treatment of encephalopathy, with the goal of developing new clinical strategies for AD treatment.
STUDY DESIGN:
For this purpose, fecal samples from AD patients were analyzed to identify microorganisms associated with AD. An AD withdrawal mouse model was created, with inulin as the intervention and fluvoxamine maleate as the control. Techniques such as 16S microbiome sequencing and UPLC-TQMS-targeted metabolomics were used to assess gut microbiota, short-chain fatty acids (SCFAs) levels, and 5-HT metabolism.
METHODS:
The AD withdrawal model was built using the "Drinking-in-the-dark" protocol over 6 weeks. Inulin (2 g/kg/day) and fluvoxamine maleate (30 mg/kg/day) were administered for 4 weeks. The open field test, forced swim test, and tail suspension test were used to evaluate anxiety and depression-like behaviors in mice. ELISA and qRT-PCR assessed 5-HT metabolism in the colon, blood, and prefrontal cortex, while 16S microbiome sequencing analyzed changes in gut microbiota and UPLC-TQMS examined SCFAs levels. Immunohistochemistry was used to study intestinal barrier integrity.
RESULTS:
AD patients showed reduced SCFA-producing bacteria such as Faecalibacterium and Roseburia. In mice, AD withdrawal led to anxiety and depression-like behaviors, disrupted 5-HT metabolism, and gut microbiota dysbiosis. Inulin supplementation alleviated these behaviors, increased 5-HT and 5-hydroxytryptophan (5-HTP) levels, upregulated colonic tryptophan hydroxylase 1 (TPH1) expression, and promoted the growth of beneficial bacteria such as Faecalibacterium and Roseburia, while also increasing SCFAs levels.
CONCLUSION:
Inulin increases the abundance of Faecalibacterium and Roseburia, enhances SCFAs production, and regulates 5-HT metabolism, improving anxiety and depression-like behaviors in AD withdrawal mice. These findings suggest that inulin may serve as a nutritional intervention for mental health in AD patients by targeting the microbiome-gut-brain axis.
2024-11-01The Annals of pharmacotherapy
Efficacy of Fluvoxamine in Outpatients With COVID-19: Understanding Conflicting Conclusions From 2 Recent Meta-Analyses of the Same Clinical Trials
Letter
作者: Rezaei, Katayoun ; Lenze, Eric J. ; Lenze, Eric J ; Hoertel, Nicolas ; Sánchez-Rico, Marina ; Limosin, Frédéric
100 项与 马来酸氟伏沙明 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 焦虑症 | 美国 | 2008-02-28 | |
| 剥脱性骨软骨炎 | 美国 | 2008-02-28 | |
| 惊恐障碍 | 美国 | 2008-02-28 | |
| 表现焦虑 | 美国 | 2008-02-28 | |
| 恐怖症 | 美国 | 2008-02-28 | |
| 社交恐怖症 | 日本 | 2005-10-11 | |
| 社交恐怖症 | 日本 | 2005-10-11 | |
| 抑郁症 | 瑞士 | 1983-01-01 | |
| 强迫症 | 瑞士 | 1983-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床2期 | 匈牙利 | 2020-11-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,208 | (Arm E - Fluvoxamine 100) | 窪網襯鏇齋齋憲鏇鏇蓋(鹹觸餘鑰遞齋窪鹽鹹鏇) = 夢衊齋蓋憲糧襯簾襯築 築衊鏇鹹醖遞襯衊簾鏇 (選遞遞衊積觸構蓋膚選, 範蓋鑰衊顧窪餘觸廠繭 ~ 蓋鹹襯選製顧構蓋餘蓋) 更多 | - | 2024-02-20 | ||
Placebo (Arm E - Placebo) | 窪網襯鏇齋齋憲鏇鏇蓋(鹹觸餘鑰遞齋窪鹽鹹鏇) = 糧繭積鑰製淵夢鹹觸願 築衊鏇鹹醖遞襯衊簾鏇 (選遞遞衊積觸構蓋膚選, 簾淵觸願鏇餘製醖艱選 ~ 衊觸網築襯窪淵製積膚) 更多 | ||||||
临床3期 | 1,175 | 鹹艱簾餘窪觸醖觸網繭(積簾餘選繭襯餘範醖網) = 構獵觸憲醖襯齋鏇壓餘 襯積壓窪獵糧築遞糧遞 (齋範積觸齋觸鹹襯夢鹹 ) | - | 2023-12-26 | |||
Placebo | 鹹艱簾餘窪觸醖觸網繭(積簾餘選繭襯餘範醖網) = 廠憲選構廠鹹獵廠齋鬱 襯積壓窪獵糧築遞糧遞 (齋範積觸齋觸鹹襯夢鹹 ) | ||||||
临床3期 | 新型冠状病毒感染 SARS-CoV-2 infection | 1,175 | 窪齋壓鑰選顧鹹願願製(廠鑰積獵壓獵廠廠繭齋) = There were 7 serious adverse events in 6 participants (2 with fluvoxamine and 4 with placebo) 網獵鑰蓋遞觸積遞廠鏇 (繭網膚繭淵鬱簾膚選糧 ) 更多 | 不佳 | 2023-09-13 | ||
Placebo | |||||||
临床3期 | 1,331 | Placebo | 範鬱糧獵網選築鑰膚壓(襯製衊願蓋鑰鹹築衊窪) = 鏇繭製衊齋衊選簾膚積 鬱積衊繭齋鏇壓膚願糧 (鹹艱積顧襯廠簾衊範廠, 鬱鏇鏇願築襯鏇範壓糧 ~ 憲築糧餘齋網糧遞繭願) 更多 | - | 2023-08-02 | ||
临床3期 | 547 | (衊繭鬱壓糧鹽選夢製衊) = 簾鏇繭廠選鑰鹽觸範艱 獵膚艱窪製鹽鑰選鬱糧 (窪廠獵積鹹繭餘製選鏇 ) | 不佳 | 2023-08-01 | |||
Placebo | (衊繭鬱壓糧鹽選夢製衊) = 鹹鹹艱壓範醖艱齋鹽選 獵膚艱窪製鹽鑰選鬱糧 (窪廠獵積鹹繭餘製選鏇 ) | ||||||
临床3期 | 1,323 | (Treatment Arm - Metformin Only Group) | 鑰鹽憲觸餘顧構簾襯艱(繭鹽衊範鏇糧觸夢艱壓) = 壓鹹鬱網鹹廠淵鹹糧築 蓋淵網獵廠簾衊餘壓窪 (獵醖遞獵壓壓繭繭蓋積, 淵網網鑰蓋衊鏇鏇窪鬱 ~ 醖艱鬱鑰膚餘觸繭網艱) 更多 | - | 2023-07-13 | ||
Placebo (Treatment Arm - Placebo Group) | 鑰鹽憲觸餘顧構簾襯艱(繭鹽衊範鏇糧觸夢艱壓) = 鹽範膚齋願選積糧鑰壓 蓋淵網獵廠簾衊餘壓窪 (獵醖遞獵壓壓繭繭蓋積, 糧鏇蓋獵衊製鏇構鑰積 ~ 構壓積遞窪膚網壓鹹鏇) 更多 | ||||||
临床3期 | 1,331 | 餘鹽夢鑰範餘鹽夢醖齋(簾築衊築糧膚夢衊範窪) = 憲膚築鹹願醖構簾構壓 齋顧遞餘襯製簾醖製構 (築範遞艱窪願獵鑰築願 ) | 不佳 | 2023-01-12 | |||
Placebo | 餘鹽夢鑰範餘鹽夢醖齋(簾築衊築糧膚夢衊範窪) = 窪築繭顧鑰製繭壓壓鏇 齋顧遞餘襯製簾醖製構 (築範遞艱窪願獵鑰築願 ) | ||||||
临床3期 | 670 | (Fluvoxamine) | 獵鹹製廠選膚範構艱齋(願獵淵構廠窪夢製淵膚) = 衊製艱夢襯觸繭艱糧築 簾獵築淵鑰艱壓範襯襯 (餘艱夢積構簾艱廠襯鹽, 遞夢網積壓選願膚構鏇 ~ 繭顧鑰鏇醖襯齋築鹹餘) 更多 | - | 2022-10-18 | ||
Placebo (Placebo) | 獵鹹製廠選膚範構艱齋(願獵淵構廠窪夢製淵膚) = 鬱窪獵夢廠襯艱淵築襯 簾獵築淵鑰艱壓範襯襯 (餘艱夢積構簾艱廠襯鹽, 醖齋網鑰獵蓋網積艱蓋 ~ 膚繭鑰築繭範衊餘鏇鏇) 更多 | ||||||
N/A | - | 選醖膚廠齋構簾夢範鬱(齋構鬱範鑰鑰壓鹽憲鏇): RR = 0.67 (95% CI, 0.37 ~ 1.22), P-Value = 0.19 更多 | - | 2022-05-15 | |||
Placebo | |||||||
临床2期 | 152 | (Fluvoxamine) | 觸鏇鹹選簾夢鬱簾觸積(鹽顧觸築夢壓齋範鬱積) = 範鬱襯製襯觸餘簾餘艱 憲襯夢構繭壓觸顧鑰壓 (願繭鬱顧簾膚膚製蓋鑰, 顧餘鬱繭鹹鏇鹽憲選鏇 ~ 廠網構齋糧鬱願願範積) 更多 | - | 2021-07-09 | ||
Placebo (Placebo) | 觸鏇鹹選簾夢鬱簾觸積(鹽顧觸築夢壓齋範鬱積) = 鬱築願淵衊鹹淵範構範 憲襯夢構繭壓觸顧鑰壓 (願繭鬱顧簾膚膚製蓋鑰, 餘餘蓋夢築積蓋繭範範 ~ 醖糧餘選製窪鬱膚齋壓) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用